Blocking SDF-1a/CXCR4 downregulates PDGF-B and Inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in ewing tumors

Molecular Cancer Therapeutics

Volumn 13, Issue 2, 2014, Pages 483-491

  Hamdan, Randala ^a   Zhou, Zhichao ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; PLATELET DERIVED GROWTH FACTOR B; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL DIFFERENTIATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PERICYTE; PROCEDURES; SARCOMA, EWING; TRANSGENIC MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINE CXCL12; DOWN-REGULATION; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTORS, CXCR4; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894117950     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0447     Document Type: Article

References (40)

1. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010;11: 184-92
2. Riggi N, Stamenkovic I. The Biology of Ewing sarcoma. Cancer Lett 2007;254:1-10
3. Anderson P, Kopp L, Anderson N, Cornelius K, Herzog C, Hughes D, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008;17:1703-15
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
5. Doi Y, Kudo H, Nishino T, Fujimoto S. [Vasculogenesis and angiogenesis]. J UOEH 2003;25:409-17
6. Kopp HG, Ramos CA, Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 2006;13:175-81
7. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004;287:C572-9
8. Bolontrade MF, Zhou RR, Kleinerman ES. Vasculogenesis plays a role in the growth of Ewing's sarcoma in vivo. Clin Cancer Res 2002; 8:3622-7
9. Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES. Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res 2008;6:929-36
10. Reddy K, Cao Y, Zhou Z, Yu L, Jia SF, Kleinerman ES. VEGF(165) expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis 2008;11:257-67
11. Zhou Z, Reddy K, Guan H, Kleinerman ES. VEGF(165), but not VEGF (189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res 2007;5:1125-32
12. Zhou Z, Bolontrade MF, Reddy K, Duan X, Guan H, Yu L, et al. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007;13:4867-73
13. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005;11:2662-9
14. Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004;35:233-45
15. Li M, Ransohoff RM. The roles of chemokine CXCL12 inembryonic and brain tumor angiogenesis. Semin Cancer Biol 2009;19:111-5
16. De Falco E, Porcelli D, Torella AR, Straino S, Iachininoto MG, Orlandi A, et al. SDF-1 involvement in endothelial phenotype and ischemiainduced recruitment of bone marrow progenitor cells. Blood 2004; 104:3472-82
17. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001;97:3354-60
18. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927-31
19. Reddy K, Zhou Z, Jia SF, Lee TH, Morales-Arias J, Cao Y, et al. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer 2008;123:831-7
20. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 2005;7:452-64
21. Diaz-Flores L, Gutierrez R, Madrid J, Varela H, Valladares F, Acosta E, et al. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol 2009;24:909-69
22. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-9
23. Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, et al. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 2007;67:7358-67
24. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 2004;15: 197-204
25. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009;77:1655-64
26. Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncol 2007;3:19-27
27. Schadler KL, Zweidler-McKay PA, Guan H, Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 2010;16:848-56
28. Hamdan R, Zhou Z, Kleinerman ES. SDF-1alpha induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. Mol Cancer Res 2011;9:1462-70
29. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007; 13:4503-10
30. Stewart KS, Kleinerman ES. Tumor vessel development and expansion in Ewing's Sarcoma: a review of the vasculogenesis process and clinical trials with vascular-targeting agents. Sarcoma 2011;2011: 165837
31. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001;938:36-45; discussion -7
32. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-20
33. Maksym RB, Tarnowski M, Grymula K, Tarnowska J, Wysoczynski M, Liu R, et al. The role of stromal-derived factor-1-CXCR7 axis in development and cancer. Eur J Pharmacol 2009;625:31-40
34. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280: 35760-6
35. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006;203: 2201-13
36. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol 2009;75:1240-7
37. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111: 1287-95
38. Kasuya K, Nagakawa Y, Suzuki M, Suzuki Y, Kyo B, Suzuki S, et al. Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma. Exp Ther Med 2012;3:599-602
39. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316-23
40. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 2013; 23: 522-32.